dr. yu on initial findings from the keynote-365 trial in mcrpc
Published 5 years ago • 60 plays • Length 2:05Download video MP4
Download video MP3
Similar videos
-
1:15
dr. yu on rationale for the keynote-365 study in mcrpc
-
2:58
evan yu, md, elaborates on the results from keynote 365 in mcrpc
-
2:47
dr. antonarakis on updated analysis of the keynote-199 trial in mcrpc
-
1:28
dr. yu on trials of moderate hypofractionation in prostate cancer
-
1:13
dr. yu on the role of pet imaging in prostate cancer
-
1:10
dr. yu on the future of castration-sensitive prostate cancer
-
1:14
dr. yu on combining pembrolizumab and olaparib in mcrpc
-
2:03
key takeaways from keynote-365 in metastatic castration-resistant prostate cancer
-
18:52
can financial engineering and data science cure cancer? by andrew w. lo
-
34:34
active surveillance of prostate cancer with yushen qian, md
-
4:14
#prostatecancer doctors: how to choose the right one for you | joel nowak, ceo of cancer abcs | pcri
-
0:50
dr. graff on the keynote-641 trial in mcrpc
-
1:51
dr. yu discusses the utility of gtx-758 in mcrpc
-
1:32
dr. hussain on results of the profound trial in mcrpc
-
1:53
william oh, md, tells us about the results of keynote-365 in mcrpc
-
1:37
dr. agarwal on the talapro-2 trial in mcrpc
-
0:59
dr. yu on future directions in prostate cancer
-
1:00
dr. yu on moderate hypofractionation in prostate cancer
-
2:18
evan yu, md, regarding combination pembrolizumab and olaparib in mcrpc
-
1:06
dr. yu on comorbidities and therapy choice in prostate cancer
-
1:39
dr. howard scher on corticosteroids during treatment with enzalutamide in mcrpc
-
2:33
dr. yu on novel pet imaging in prostate cancer